Inclisiran Clinical Trial: The Future of LDL-C Management in Primary Care High cholesterol is a significant contributor to cardiovascular diseases (CVD), affecting millions globally. While statins have long been the first-line therapy for reducing low-density...
💰 Biggest Investment in General Practice in a Decade The 2025/26 GP contract introduces the largest funding increase in over 10 years, with a 7.2% rise (£889 million), bringing the total to £13.1 billion. 💵 Financial Enhancements 📌 7.2% funding increase overall📌 £80...
The Faculty of Sexual and Reproductive Healthcare (FSRH) provides guidance on the interaction between glucagon-like peptide-1 (GLP-1) receptor agonists and hormonal contraception. Certain GLP-1 receptor agonists, such as tirzepatide, can delay gastric emptying,...
Managing the increasing prevalence of diabetes in England is expected to be a significant clinical challenge in the 21st century. Currently, 3.6 million people in England are living with diabetes, and projections indicate this number could rise to 4.2 million by 2030,...
The NHS is set to save £1 billion over five years by switching to biosimilars, according to a recent report by The Pharmaceutical Journal  As the NHS continues to face financial pressures, biosimilars offer a cost-effective alternative to biologic medicines without...